ABP 654, the first FDA-approved interchangeable ustekinumab biosimilar, will enter the US market in January 2025. In vitro studies confirmed ABP 654's functional similarity to EU and US reference ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results